Leerink upgraded Aclaris to ‘Outperform’ from ‘Market Perform’ with its price target raised to $7 from $2; Piper Sandler upgraded the company to ‘Overweight’ from ‘Neutral.’
Aclaris Therapeutics announced a private placement of 35.56 million shares, raising approximately $80 million for R&D and corporate purposes.Quiver AI SummaryAclaris Therapeutics, Inc. announced that it...
Aclaris expands its pipeline with Biosion's innovative biologics, enhancing leadership and financial position for future growth.Quiver AI SummaryAclaris Therapeutics has announced a strategic advancement...
USA News Group – Known as one of the most deadly forms of cancer, pancreatic cancer still has the highest mortality rate of all major cancers today. However, researchers and the biotech sector are working...